Key Studies Directly Comparing Lurbinectedin to Similar Drugs
Lurbinectedin (Zepzelca), approved for small cell lung cancer (SCLC), has been compared to topotecan—the standard second-line chemotherapy—in the phase 3 ATLANTIS trial. This randomized study of 421 patients with relapsed SCLC showed lurbinectedin plus irinotecan did not improve overall survival (median 8.6 months) over topotecan (7.6 months; HR 0.95, p=0.55). Progression-free survival also showed no benefit (median 5.0 vs. 4.1 months; HR 0.93). Lurbinectedin had a better safety profile, with fewer grade ≥3 hematologic toxicities.[1][2]
The pivotal phase 2b trial leading to FDA approval compared lurbinectedin monotherapy to historical topotecan controls, reporting higher response rates (35% vs. 14%) and better tolerability.[3]
How Lurbinectedin Stacks Up Against Other SCLC Treatments Like Irinotecan Alone
Indirect comparisons and smaller studies position lurbinectedin against irinotecan monotherapy. A phase 2 trial found lurbinectedin achieved a 21% response rate and median survival of 15.2 months in sensitive relapse SCLC, outperforming single-agent irinotecan (response ~10-15%) from prior data. Network meta-analyses of relapsed SCLC trials rank lurbinectedin favorably for progression-free survival over irinotecan and topotecan.[4][5]
No head-to-head trials exist with immunotherapy like atezolizumab or immunotherapy-chemotherapy combos (e.g., durvalumab-tremelimumab), though real-world data suggest lurbinectedin as a post-immunotherapy option with 26% response rates.[6]
Comparisons in Other Cancers Like Mesothelioma or Ovarian Cancer
In malignant pleural mesothelioma, a phase 2 trial compared lurbinectedin to active controls (gemcitabine or vinorelbine), yielding disease control rates of 50% vs. 33%, with median progression-free survival of 4.3 months.[7]
For platinum-resistant ovarian cancer, phase 2 data showed lurbinectedin response rates of 12%, similar to weekly paclitaxel (10-15%) or pegylated liposomal doxorubicin, but with less neuropathy.[8]
Ongoing Trials and Future Head-to-Head Comparisons
NCT02454972 (CORALL trial) explores lurbinectedin vs. physician's choice (topotecan, cyclophosphamide, or bendamustine) in SCLC. Phase 3 trials like LAGOON (NCT05143279) test lurbinectedin-irinotecan vs. standard care. Basket trials (e.g., NCT03204825) compare it to doxorubicin in HR-deficient tumors.[9]
No patents directly cover these comparisons on DrugPatentWatch.com, as lurbinectedin’s key patents focus on the molecule itself (expiring 2032-2035).[10]
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa2117913
[2] https://pubmed.ncbi.nlm.nih.gov/35294813/
[3] https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30355-6/fulltext
[4] https://pubmed.ncbi.nlm.nih.gov/33653841/
[5] https://www.jto.org/article/S1556-0864(21)02245-0/fulltext
[6] https://pubmed.ncbi.nlm.nih.gov/35114287/
[7] https://pubmed.ncbi.nlm.nih.gov/33866081/
[8] https://pubmed.ncbi.nlm.nih.gov/29356545/
[9] https://clinicaltrials.gov
[10] https://www.drugpatentwatch.com/p/tradename/ZEPZELCA